NASDAQHealth CareBiotechnologySnapshot 2026-07-23
Reading IDYA? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a speculative growth opportunity in the healthcare sector. The current thesis state is mixed, with some positive developments but also notable risks ahead.
The market currently reflects a durable premium for IDYA compared to its peers, indicating that investors expect significant growth. However, there is an expectations gap, suggesting that some of these growth assumptions may not be fully justified.
Fundamentals are likely to remain mixed in the near term. Management's focus on advancing clinical collaborations and revenue growth shows promise, but recent declines in collaboration revenue and a high probability of missing earnings add uncertainty.
The thesis hinges on the performance of sector bellwethers and IDYA's ability to execute on its clinical priorities. Positive developments in the healthcare sector could provide a tailwind, while any negative guidance or earnings misses could weigh heavily on the stock.
In the next 1 to 3 years, IDYA's prospects will depend on successful clinical advancements and sector performance. Not investment advice.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The clinical collaboration with Roche enhances growth potential and reinforces the positive outlook for the company. There are no significant threats noted that would weaken this assessment.
as of 2026-07-23
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: An increase in revenue shows progress in fixing recent drops and challenges.
Confirms:Q2 revenue is over $6.56M, showing recovery from a big drop in Q1.
Disproves:Q2 revenue remains below $6.56M, continuing the downward trend.
Why it matters: Higher operating income means better cost control. It also shows more efficiency.
Confirms:Operating income goes from -$108.5M in Q1 to less negative or positive in Q2.
Disproves:Operating income worsens or remains at -$108.5M or worse in Q2.
Why it matters: Revenue growth is key for the company's future and for investor trust.
Confirms:Q2 earnings report shows revenue growth above 10% year over year.
Disproves:Q2 revenue growth remains below 5% year over year.
Why it matters: Good results could raise trust in IDEAYA's projects and growth.
Confirms:IDEAYA announced good results for IDE892 with Roche's RG6505.
Disproves:Bad results or delays in the work with Roche.
Why it matters: Updates will show how well darovasertib works in HLA*A2-positive patients.
Confirms one read:Data shows improved overall response rate in HLA*A2-positive mUM patients.
Confirms the other:Data shows no big effect in HLA*A2-positive patients.
